Title: AstraZeneca, LegoChem Biosciences To
Co-Develop Novel Antibiotics Publication: Asian Scientist Date: 24 Dec 2012 URL: link to website
Summary
AstraZeneca has licensed an
antibiotic drug candidate from South Korea’s LegoChem Biosciences to treat
drug-resistant bacterial infections. About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |
|
IP : 106.243.208.*** 
|
